Navalign LLC Buys 208 Shares of Zoetis Inc. (NYSE:ZTS)

Navalign LLC boosted its stake in shares of Zoetis Inc. (NYSE:ZTS) by 4.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,888 shares of the company’s stock after buying an additional 208 shares during the quarter. Navalign LLC’s holdings in Zoetis were worth $965,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Evermay Wealth Management LLC raised its holdings in shares of Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after purchasing an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC raised its holdings in shares of Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after purchasing an additional 112 shares in the last quarter. Worth Asset Management LLC bought a new stake in shares of Zoetis in the 1st quarter valued at about $26,000. VisionPoint Advisory Group LLC purchased a new position in shares of Zoetis in the 2nd quarter worth approximately $29,000. Finally, Moisand Fitzgerald Tamayo LLC grew its position in shares of Zoetis by 105.5% in the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after buying an additional 96 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 923 shares of Zoetis stock in a transaction on Monday, March 18th. The shares were sold at an average price of $173.33, for a total value of $159,983.59. Following the transaction, the executive vice president now directly owns 15,723 shares in the company, valued at approximately $2,725,267.59. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Over the last ninety days, insiders have sold 2,209 shares of company stock worth $408,453. Insiders own 0.12% of the company’s stock.

Zoetis Stock Up 0.4 %

Shares of ZTS traded up $0.61 during mid-day trading on Thursday, hitting $169.12. 3,395,584 shares of the company’s stock were exchanged, compared to its average volume of 2,739,733. The company has a market cap of $77.43 billion, a price-to-earnings ratio of 33.36, a P/E/G ratio of 2.53 and a beta of 0.87. Zoetis Inc. has a fifty-two week low of $151.03 and a fifty-two week high of $201.92. The company has a debt-to-equity ratio of 1.32, a quick ratio of 2.00 and a current ratio of 3.36. The stock’s 50-day moving average is $185.92 and its 200-day moving average is $182.24.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The business’s revenue for the quarter was up 8.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.15 earnings per share. On average, sell-side analysts anticipate that Zoetis Inc. will post 5.8 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.02%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on ZTS shares. Jefferies Financial Group reaffirmed a “buy” rating and issued a $230.00 price objective on shares of Zoetis in a research report on Tuesday, December 19th. Piper Sandler lifted their price objective on shares of Zoetis from $215.00 to $220.00 and gave the company an “overweight” rating in a research note on Tuesday, February 20th. Stifel Nicolaus lifted their price objective on shares of Zoetis from $195.00 to $215.00 and gave the company a “buy” rating in a research note on Friday, January 12th. BNP Paribas began coverage on shares of Zoetis in a research report on Thursday, December 7th. They set an “outperform” rating and a $237.00 price objective for the company. Finally, The Goldman Sachs Group upped their target price on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $224.33.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.